News

HDA Media And Political Bulletin – 27 June 2016

Pharma concerned as UK votes for “Brexit”

24 June 2016, pharmaphorum, Richard Staines

 

Pharmaphorum reports on the pharma industry’s reaction to the UK voting to leave the EU. The ABPI issued a statement explaining that the Association was committed to working closely with the authorities to tackle the challenges that an exit from the European Union poses. In addition, the European Medicines Agency (EMA) stated that it was business as usual and will share concrete information as it comes.

 

The full ABPI statement is available here.

 

Parliamentary Coverage

 

There is no Parliamentary coverage today.

 

Full Coverage

Pharma concerned as UK votes for “Brexit”

24 June 2016, pharmaphorum, Richard Staines

 

The UK has voted to leave the European Union in a “Brexit” move that will have wide political and economic consequences – including for the pharma and life sciences industry.

 

Prime minister David Cameron has already announced that he is to step down and that a new prime minister will be in place by October, but there are many unanswered questions.

 

The news that Britain had voted to leave sent shares and the value of the pound plunging amid the uncertainty.

 

The Association of the British Pharmaceutical Industry (ABPI) trade body had championed remaining in the EU from the outset.

 

As the nation went to the polls on Thursday, the ABPI joined 1,280 businesses in signing a letter to remain.

 

But following a vote that swung in favour of leaving the EU, ABPI CEO Mike Thompson said in a statement: “The voice of the British people has been heard. This creates immediate challenges for future investment, research and jobs in our industry in the UK. With that being the case, we are committed to working closely with the government to agree what steps need to be taken to send a strong signal that the UK is open for business.”

 

Britain has particularly strong links with Europe in medicines regulation – the European Medicines Agency is based in London and the Brexit decision almost certainly means the regulator will move in the longer term.

 

In a statement, an EMA spokesperson said it was business as usual and that the regulator will continue with its mission to protect human and animal health.

 

A spokesperson said: “The people in the UK have taken their vote and it is now up to the UK government to decide how to act upon the outcome of the referendum.

 

“No country has ever decided to leave the EU, so there is no precedent for this situation. It is too early to foresee the implications of this decision and at this stage we are waiting for further guidance from the European Commission. Whenever we have concrete information we will share it.”

 

In a statement, the Ethical Medicines Industry Group (EMIG), representing small and medium sized pharma in the UK, said: “EMIG is concerned with the UK electorate’s decision to leave the EU.

 

“This decision will undermine the position of the UK in its critical role as the regulatory gateway for US and other biotech companies to the entire EU market.

 

“It will downgrade the value of the UK as a world-class scientific research centre and therefore make it less attractive as for investment and the best global research minds.

 

“Ultimately, this is an unfortunate decision for patients and the opportunity for access to the most up to date innovative medicines.”

 

The European Federation of Pharmaceutical Industries and Associations (EFPIA), representing European pharma, said: “EFPIA shares the common goal of ensuring rapid access to innovative medicines for patients across Europe, as well as developing a regulatory and policy environment that fosters innovation and supports the research and development of new medicines to meet the needs of patients, healthcare systems and society.

 

“As an industry, over the coming months, we are committed to engaging with stakeholders both in Europe and in the UK to support these objectives.”

HDA Media And Political Bulletin – 27 June 2016

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?